Pak Emirates Military Hospital Rawalpindi, Pakistan.
Pak Emirates Military Hospital/National University of Medical Sciences, Rawalpindi, Pakistan.
J Ayub Med Coll Abbottabad. 2022 Apr-Jun;34(2):321-325. doi: 10.55519/JAMC-02-9469.
This cross-sectional study is aimed at evaluating the association of mediastinal lymphadenopathy with COVID-19 prognosis in severe cases. Place and Duration of Study: Department of Medicine, Pak Emirates Military Hospital, Pakistan, from June to July 2020.
One hundred and fifty (150) laboratory-confirmed SARS CoV-2 infected, severe cases in Intensive Care Unit/ High Dependency Unit were included. These cases were divided into two categories, i.e., with and without mediastinal lymphadenopathy on High Resolution Computed Tomography chest. The two categories were compared on the basis of data obtained including age, gender, comorbid, White Blood Cell count, lymphocyte count, median days of hospitalization, need for invasive ventilation, Intensive Care Unit admission, clinical outcome and High-Resolution Computed Tomography chest findings. The data was compiled on a questionnaire and analysed on SPSS 24.
Total 155 severe COVID-19 patients were reviewed, out of which 36 (23.2%) had mediastinal lymphadenopathy (category 1) and 119 (76.8%) had no mediastinal lymphadenopathy (category 2). Laboratory findings including median of white blood cells and lymphocyte percentage had no significant change in both categories. Intensive care unit admissions were 12 (33.3%) and 56 (47.1%) in category 1 and 2 respectively. Median days of hospitalization (8 days) and mortality rate (16%) were almost the same in both categories.
Our study concludes that presence of mediastinal lymphadenopathy in severe COVID-19 cases is not associated with worse outcome. However, overall prevalence of mediastinal lymphadenopathy in severe cases is high (23.2%).
本横断面研究旨在评估纵隔淋巴结肿大与 COVID-19 重症预后的关系。
巴基斯坦 Pak Emirates 军事医院内科，2020 年 6 月至 7 月。
纳入 150 例实验室确诊的 SARS-CoV-2 感染重症患者，包括重症监护病房/高依赖病房。这些病例分为纵隔淋巴结肿大和无纵隔淋巴结肿大两组，根据获得的数据进行比较，包括年龄、性别、合并症、白细胞计数、淋巴细胞计数、住院中位数、需要有创通气、入住重症监护病房、临床结局和高分辨率胸部 CT 表现。数据汇总在问卷上，并使用 SPSS 24 进行分析。
共回顾了 155 例重症 COVID-19 患者，其中 36 例（23.2%）有纵隔淋巴结肿大（第 1 类），119 例（76.8%）无纵隔淋巴结肿大（第 2 类）。两组实验室检查结果，包括白细胞中位数和淋巴细胞百分比均无明显变化。第 1 类和第 2 类患者入住重症监护病房的比例分别为 12 例（33.3%）和 56 例（47.1%）。住院中位数（8 天）和死亡率（16%）在两组几乎相同。
本研究表明，COVID-19 重症患者纵隔淋巴结肿大与不良预后无关。然而，重症患者纵隔淋巴结肿大的总体患病率较高（23.2%）。
